The Clinical Significance of HER2+ Breast Cancer and Opportunities for Improved Outcomes
ASCO® 2024 Insights: "Updated Survival Data in DESTINY-Breast03 Trial - T-DXd vs. T-DM1 in Patients With HER2+ mBC"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Erika Hamilton
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Erika Hamilton
Login to view comments.
Click here to Login